William Looney

https://t.co/fazjXQ6Dky

#CNN

InVivo cover feature #HackAttacck pegs issues facing biopharma Chief Info Security Officers (CISOs) -- threat is REAL!

https://t.co/cv7FWiq2Lq

#FutureOf Aetna CEO Bertolini - no decision yet on participation in ACA exch for 2018. Earliest date for ACA replacement launch: 1-1-19

#FutureOf WSJ talks to Aetna CEO Bertolini on priorities ex Humana merger: 1. expand Medicare Adv LOB; 2. scale-up community/home HC biz.

#BIOCEO17 JKim CEO Inovio: IO space 2b "commoditized" in 5 years, with 11 active players up from 4 tday. Vaccine the next differentiator.

The New World Of Pharma – Markets, Messaging And The Flash Mob https://t.co/75Lc8zTq4Z

RT @INVIVOnow: #Pharma's Reputation In A Post-Fact World https://t.co/fWzmTCsL1C via @BillInVivo https://t.co/hqFtgi0NeR

Did you have the most successful early phase trial (preclin&phase1) we want to recognize your excellence https://t.co/j9QzbNYvdV #CARE2017

Pharma's Reputation In A Post-Fact World https://t.co/lGcOKU6X3Z

RT @PharmExecutive: .@JimGreenwood of @IAmBiotech: #biopharma companies should no longer consider the #FDA an obstacle to #innovation https…

Loss of Exclusivity: Key approaches to preserving meaningful value well into the post-patent-loss future #pharma https://t.co/EokqFASrqd https://t.co/GnFR4xaTS9

RT @PharmExecutive: Jeremy Desai of Apotex, #Canada’s largest #generics producer, discusses the impact of #pharma's pricing pressure https:…

RT @PharmExecutive: The November issue of Pharm Exec Digital Edition is Now Online!, download here #pharma #healthcare #biopharma https://t…

RT @PharmExecutive: Our Editorial Advisory Board member Les Funtleydar gives his thoughts on the #biopharma marketplace #healthcare https:/…

Pondering #WhyHeWon…? a look back to one of 2015’s most cited #PopHealth papers on midlife mortality reversal #tbt https://t.co/jEIks5CDiM